SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 104.18+0.1%Nov 17 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tnsaf who wrote (2681)10/14/2011 10:20:07 AM
From: Biomaven   of 3202
 
I've now seen some analyst reports defending INCY, and they make some reasonable points.

Key seems to be that this trial had a wide dosage variation - some doses that were too low and some that were too high. So you would get discontinuations for both efficacy and for tox. Those discontinuations in turn would drive no improvement in OS. Also, the rebound effects claimed here do not seem to have been repeated in other trials for whatever reason.

So I'm starting to wonder if the weakness was an overreaction.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News